Cronos Group (TSE:CRON) PT Lowered to C$4.30 at Cowen

Cronos Group (TSE:CRONGet Rating) had its target price trimmed by Cowen to C$4.30 in a research report sent to investors on Tuesday morning, Stock Target Advisor reports. The brokerage currently has a na rating on the stock.

CRON has been the topic of several other reports. Barclays raised shares of Cronos Group to a hold rating and set a C$5.00 price objective on the stock in a research report on Tuesday, March 22nd. Cowen cut their price objective on shares of Cronos Group from C$4.50 to C$4.30 in a research report on Tuesday. Jefferies Financial Group increased their price objective on shares of Cronos Group from C$3.70 to C$4.30 in a research report on Thursday, May 12th. CIBC upgraded shares of Cronos Group to a buy rating in a research note on Wednesday, May 11th. Finally, Canaccord Genuity Group upgraded shares of Cronos Group to a hold rating and set a C$4.50 target price on the stock in a research note on Wednesday, May 11th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of Hold and an average price target of C$5.49.

Cronos Group Stock Down 1.3 %

TSE:CRON opened at C$3.87 on Tuesday. Cronos Group has a 1-year low of C$3.32 and a 1-year high of C$9.69. The firm’s 50-day moving average price is C$3.85 and its 200-day moving average price is C$4.25. The company has a market capitalization of C$1.45 billion and a PE ratio of -4.11. The company has a debt-to-equity ratio of 0.70, a current ratio of 26.42 and a quick ratio of 25.11.

Cronos Group Company Profile

(Get Rating)

Cronos Group Inc operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets.

See Also

Analyst Recommendations for Cronos Group (TSE:CRON)

Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.